Oncologists quoted a number of reasons for prescribing panitumumab (with or without concurrent oxaliplatin-containing therapy) to patients with mutant or unknown KRAS status, with the most frequent influencing factors being the patients’ medical condition, that they were unconcerned by KRAS mutation status, the availability of tumor tissue, and the time taken for KRAS test results to be received. Here, KRAS is linked to neoplasm.